Immuron company info

What does Immuron do?
Immuron (ASX:IMC), (NASDAQ:IMRN) is an Australian-based biopharmaceutical company focusing on the research, development, and commercialization of oral immunotherapy products. Immuron's main projects aim to tackle various gastrointestinal and liver diseases, leveraging its unique platform technology to produce oral immune-modulating polyclonal antibodies. Among its leading products is Travelan, an over-the-counter product for the prevention of travelers' diarrhea, and a pipeline of pre-clinical candidates targeting severe liver diseases, including NASH (Non-alcoholic steatohepatitis). Immuron's objective is to harness its proprietary technology to create therapies that improve health outcomes for patients worldwide dealing with immune-mediated and infectious diseases, constantly striving to expand its product portfolio and research capabilities to address unmet medical needs.
Immuron  company media
Company Snapshot

Is Immuron a public or private company?

key
Ownership
Public

How many people does Immuron employ?

people
Employees
6

What sector is Immuron in?

pie chart
Sector
Health Care

Where is the head office for Immuron ?

location pin
Head Office
Blackburn North, Australia

What year was Immuron founded?

founded flag
Year Founded
1994
What does Immuron specialise in?
/Therapeutic Antibodies /Anti-Inflammatory Treatments /Travelan Products /Gastrointestinal Diseases /Liver Treatment /Immunotherapies Development

What are the products and/or services of Immuron ?

Overview of Immuron offerings
Travelan, an over-the-counter product aimed at preventing travelers' diarrhea, utilizing antibodies to combat harmful bacteria.
IMM-124E, a clinical-stage project targeting immune-mediated and inflammatory diseases, including NASH (Non-alcoholic steatohepatitis).
IMM-529, a therapeutic candidate designed for Clostridium difficile infections, focusing on both prevention and treatment of this severe gastrointestinal infection.
A research initiative focused on developing treatments for colitis and irritable bowel syndrome, leveraging its expertise in immunotherapy and gut health.
Partnerships with the U.S. Department of Defense and Naval Medical Research Center to develop vaccines and treatments against enterotoxigenic Escherichia coli and Shigella.
Collaboration with leading universities and research institutions to explore potential therapeutic applications of its technology platform for infectious diseases and immune modulation.

Who is in the executive team of Immuron ?

Immuron leadership team
  • Mr. Steven George Lydeamore CPA, M.B.A.
    Mr. Steven George Lydeamore CPA, M.B.A.
    Chief Executive Officer
  • Dr. Jerry  Kanellos Ph.D.
    Dr. Jerry Kanellos Ph.D.
    Chief Operating Officer
  • Mr. Flavio  Palumbo
    Mr. Flavio Palumbo
    Chief Commercial Officer
  • Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A.
    Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A.
    CFO & Company Secretary
  • Mr. David  Lyon
    Mr. David Lyon
    Head of Marketing